129 related articles for article (PubMed ID: 35304238)
1. Priming treatment with T-cell redirecting bispecific antibody ERY974 reduced cytokine induction without losing cytotoxic activity in vitro by changing the chromatin state in T cells.
Iwata Y; Narushima Y; Harada A; Mishima M
Toxicol Appl Pharmacol; 2022 Apr; 441():115986. PubMed ID: 35304238
[TBL] [Abstract][Full Text] [Related]
2. Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.
Iwata Y; Sasaki M; Harada A; Taketo J; Hara T; Akai S; Ishiguro T; Narita A; Kaneko A; Mishima M
Toxicol Appl Pharmacol; 2019 Sep; 379():114657. PubMed ID: 31326447
[TBL] [Abstract][Full Text] [Related]
3. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
[TBL] [Abstract][Full Text] [Related]
4. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
5. In vitro toxicological support to establish specification limit for anti-CD3 monospecific impurity in a bispecific T cell engager drug, ERY974.
Harada A; Shioda A; Ikuno T; Iwata Y; Shiraiwa H; Wakabayashi T; Sano Y; Mishima M
Toxicol In Vitro; 2020 Aug; 66():104841. PubMed ID: 32247040
[TBL] [Abstract][Full Text] [Related]
6. Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.
Sano Y; Azuma Y; Tsunenari T; Kayukawa Y; Shinozuka J; Fujii E; Amano J; Nishito Y; Maruyama T; Kinoshita Y; Sakamoto Y; Yoshida A; Miyazaki Y; Sato Y; Teramoto-Seida C; Ishiguro T; Tanaka T; Kitazawa T; Endo M
Nat Commun; 2022 Sep; 13(1):5265. PubMed ID: 36071036
[TBL] [Abstract][Full Text] [Related]
7. Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial.
Komatsu SI; Kayukawa Y; Miyazaki Y; Kaneko A; Ikegami H; Ishiguro T; Nakamura M; Frings W; Ono N; Sakata K; Fujii T; Kishishita S; Kitazawa T; Endo M; Sano Y
Sci Rep; 2022 Jul; 12(1):12312. PubMed ID: 35853994
[TBL] [Abstract][Full Text] [Related]
8. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
9. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity.
Li J; Piskol R; Ybarra R; Chen YJ; Li J; Slaga D; Hristopoulos M; Clark R; Modrusan Z; Totpal K; Junttila MR; Junttila TT
Sci Transl Med; 2019 Sep; 11(508):. PubMed ID: 31484792
[TBL] [Abstract][Full Text] [Related]
10. A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities.
Chen X; Kamperschroer C; Wong G; Xuan D
Clin Transl Sci; 2019 Nov; 12(6):600-608. PubMed ID: 31268236
[TBL] [Abstract][Full Text] [Related]
11. Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
Shiraiwa H; Narita A; Kamata-Sakurai M; Ishiguro T; Sano Y; Hironiwa N; Tsushima T; Segawa H; Tsunenari T; Ikeda Y; Kayukawa Y; Noguchi M; Wakabayashi T; Sakamoto A; Konishi H; Kuramochi T; Endo M; Hattori K; Nezu J; Igawa T
Methods; 2019 Feb; 154():10-20. PubMed ID: 30326272
[TBL] [Abstract][Full Text] [Related]
12. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
13. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning.
Haber L; Olson K; Kelly MP; Crawford A; DiLillo DJ; Tavaré R; Ullman E; Mao S; Canova L; Sineshchekova O; Finney J; Pawashe A; Patel S; McKay R; Rizvi S; Damko E; Chiu D; Vazzana K; Ram P; Mohrs K; D'Orvilliers A; Xiao J; Makonnen S; Hickey C; Arnold C; Giurleo J; Chen YP; Thwaites C; Dudgeon D; Bray K; Rafique A; Huang T; Delfino F; Hermann A; Kirshner JR; Retter MW; Babb R; MacDonald D; Chen G; Olson WC; Thurston G; Davis S; Lin JC; Smith E
Sci Rep; 2021 Jul; 11(1):14397. PubMed ID: 34257348
[TBL] [Abstract][Full Text] [Related]
14. Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS).
Leclercq-Cohen G; Bacac M; Klein C
Expert Opin Biol Ther; 2023 Mar; 23(3):223-225. PubMed ID: 36629122
[No Abstract] [Full Text] [Related]
15. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
[TBL] [Abstract][Full Text] [Related]
16. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
17. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
Jiang X; Chen X; Jaiprasart P; Carpenter TJ; Zhou R; Wang W
Eur J Pharm Sci; 2020 Apr; 146():105260. PubMed ID: 32058058
[TBL] [Abstract][Full Text] [Related]
18. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Schlereth B; Quadt C; Dreier T; Kufer P; Lorenczewski G; Prang N; Brandl C; Lippold S; Cobb K; Brasky K; Leo E; Bargou R; Murthy K; Baeuerle PA
Cancer Immunol Immunother; 2006 May; 55(5):503-14. PubMed ID: 16032400
[TBL] [Abstract][Full Text] [Related]
19. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 x CD19.
Klein SC; Boer LH; de Weger RA; de Gast GC; Bast EJ
Scand J Immunol; 1997 Nov; 46(5):452-8. PubMed ID: 9393627
[TBL] [Abstract][Full Text] [Related]
20. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
